Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Black Diamond Therapeutics (BDTX) Accumulated Depreciation & Amortization (2018 - 2025)

Black Diamond Therapeutics' Accumulated Depreciation & Amortization history spans 6 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 7.53% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, up 7.53%, while the annual FY2025 figure was $1.2 million, 7.53% up from the prior year.
  • Accumulated Depreciation & Amortization reached $1.2 million in Q4 2025 per BDTX's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.4 million in Q3 2025 to a low of $183000.0 in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 3 years is $896363.6, with a median of $1.1 million recorded in 2024.
  • Peak YoY movement for Accumulated Depreciation & Amortization: surged 65.1% in 2021, then grew 7.53% in 2025.
  • A 3-year view of Accumulated Depreciation & Amortization shows it stood at $246000.0 in 2021, then surged by 364.23% to $1.1 million in 2024, then increased by 7.53% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Accumulated Depreciation & Amortization are $1.2 million (Q4 2025), $1.4 million (Q3 2025), and $1.3 million (Q2 2025).